Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharma Inc (NQ: ANIP )

28.71 -2.29 (-7.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 177,461
Open 30.90
Bid (Size) 28.58 (8)
Ask (Size) 28.71 (1)
Prev. Close 31.00
Today's Range 27.88 - 30.90
52wk Range 22.73 - 60.23
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals: Q1 Earnings Insights
ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-39.11%
-39.11%
1 Month
-9.94%
-9.94%
3 Month
-21.10%
-21.10%
6 Month
-36.17%
-36.17%
1 Year
-17.74%
-17.74%

More News

Read More
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Q1 2022 Earnings Conference Call On May 10, 2022 At 08:30 AM ET
Via Benzinga
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
From ANI Pharmaceuticals, Inc.
Via Business Wire
Insider Weekends: Return Of The Meme Stocks - GameStop (GME) And AMC Entertainment (AMC)
Via Benzinga
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Rises Over 200 Points; ANI Pharmaceuticals Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Upbeat Inflation Data, Falling Oil Prices Prop Up Dow
Via Talk Markets
Mid-Day Market Update: Dow Surges Over 300 Points; Crude Oil Tumbles 8%
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; US Producer Prices Increase 0.8% In February
Via Benzinga
ANI Pharma Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
ANI Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
From ANI Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 15, 2022
Via Benzinga
ANI Pharmaceuticals's Earnings Outlook
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
From ANI Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.